|
The 2007 edition of the European Commission's annual
scoreboard of companies' spending on research and development (R&D) shows
that corporate R&D has increased by 10%, with EU-based companies increasing
their R&D investment by 7.4%. This compares to 5.3% growth reported in the
2006 edition. The scoreboard also shows an upward trend in companies' profitability
all over the world. The world's biggest investor in R&D in the 2007
Scoreboard is Pfizer of the US, with €5.8 billion. The top EU company is
DaimlerChrysler of Germany with €5.2 billion.
"We are only ever going to improve our R&D
performance if more companies see the benefit of investing in research," said European Science and Research Commissioner Janez Potočnik. "The
positive upward trend in R&D investment seen in the last two years is
encouraging, and leads me to believe that our innovation strategy is on the
right track. But we must not allow ourselves to be complacent – quite the
opposite: we should reinforce the positive measures already taken to
consolidate and improve private investment in R&D."
The EU Industrial R&D Investment Scoreboard is
published annually by the European Commission as part of its Industrial
Research Investment Monitoring activity. The figures are derived from company
accounts for the previous financial year and indicate the investment made by a
company from its own funds. The Scoreboard does not reflect where the
expenditure was made, just the origin of the company making the investment. The
Scoreboard comprises the top1000 R&D companies from the EU and the top1000
R&D companies from the rest of the world. Together, the 2000 Scoreboard companies
invested €372 billion in R&D, estimated to represent more than 85% of
corporate expenditure on R&D worldwide.
On the downside, the report shows that R&D investment
by EU companies is still growing at a lower rate than their non-EU counterparts,
a trend identified in every edition of the Industrial R&D Scoreboard
published to date. This difference is primarily explained by a growth rate in
high R&D-intensive sectors outside the EU of almost twice that within the
EU. These sectors also account for a much larger proportion of R&D outside
the EU. Nevertheless, the EU did record the highest growth in fixed capital
investment. This represents an important part of total corporate investment
that also underpins investment in innovation.
In the coming months the European Commission will publish
the 2006 EU Survey on R&D Investment Business Trends with information about
110 R&D EU companies' investment expectations for the period 2007-2009.
This survey provides new insights into company expectations about future
R&D investments and their motivations to invest in research. The
preliminary results confirm the positive trends of the 2007 Scoreboard.
Sector trends
Pharmaceuticals & biotechnology becomes the top R&D investing sector, overtaking the technology
hardware & equipment sector. This sector is represented by many EU
companies. Many pharmaceutical companies show a strong increase of R&D
investment, e.g. Merck (+24.3%), AztraZeneca (+15.5%), Roche (+15.5%), Johnson
& Johnson (+12.9%), GlaxoSmithKline (+10%).
Chemicals shows a strong
recovery in R&D investment (+9.8%), compared to the negative growth of the
previous year. This is especially pronounced in the EU group of companies
(+17%) where the large chemical companies show impressive R&D growth rates,
e.g. Bayer (+30.3%), Solvay (+20.3%) and BASF (+19.8%). This is partly due to
processes of acquisitions and concentration in the sector.
Aerospace and defence raised
its R&D investment by 12.5% continuing the trend of strong growth of the
past years. The sector's most representative companies, EADS and Boeing
increased their R&D investment by 21.2% and 47.7% respectively.
Company trends
Three EU companies keep a position within the top 10
R&D ranking: DaimlerChrysler, the top EU company with 5.2 bn EUR (5th),
GlaxoSmithKline (7th) and Siemens (8th). Four US
companies are in the top positions: Pfizer (5.8 bn EUR), Ford Motor, Johnson
& Johnson and Microsoft.
The performance of Scoreboard companies further improved in
the past year. Sales of EU companies grew by 10% and sales of US and Japanese
companies grew by about 8%. The profitability of EU companies increased further
to 11.6% (between 12.9% for the US and 7.4% for Japan).
The 2007 EU Industrial R&D Investment Scoreboard can be
downloaded from: iri.jrc.ec.europa.eu europa.eu |